The cardiovascular safety of Pheroid® in the conscious rat
Date
2019Author
Van Wyk, Riaan
Guth, Brian D.
Grobler, Anne F.
Bester, Cor
Metadata
Show full item recordAbstract
The Pheroid® technology is a patented colloidal drug delivery
system comprised of a dispersed oil phase of omega 3 and omega 6
fatty acids emulsified in N2O saturated water. Pheroid® has
pharmaceutical applicability for the enhancement of therapeutic
efficacy due to better drug exposure, reduced cytotoxicity and faster
onset of action. The purpose of this paper was to evaluate the
possible cardiovascular effects of the Pheroid® drug delivery system
in the conscious rat. Six male rats instrumented with telemetry
transmitters were used in a three-way crossover design. The effects
of single intravenous administrations of Pheroid® and oral administration of Pheroid® and pro-Pheroid® on cardiovascular parameters were measured. These parameters included arterial blood
pressure, heart rate and the ECG. As positive controls, a single
intraperitoneal dose of clonidine (0.03 mg/kg) and an oral dose of
theophylline (30 mg/kg) were also tested. No significant effects of
Pheroid® on cardiovascular parameters were observed at any time
following oral or intravenous administration. The expected effects of
clonidine (decreased heart rate) and theophylline (increased heart
rate) could be demonstrating confirming the sensitivity of the
experimental model to detect changes in the cardiovascular
parameters measured. We have demonstrated that Pheroid® has
no effects on cardiovascular function following both oral and
intravenous administration. These data showing cardiovascular safety are supportive for the use of Pheroid® for various pharmacological applications
URI
http://hdl.handle.net/10394/33325https://www.sciencedirect.com/science/article/pii/S1056871919303260
https://doi.org/10.1016/j.vascn.2019.106608